Innovent Biologics, Inc. has announced promising results from its Phase 1 studies evaluating IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, in patients with advanced colorectal cancer. The data, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, indicate that IBI363, both as monotherapy and in combination with bevacizumab, shows encouraging responses and overall survival benefits. These findings are particularly noteworthy given colorectal cancer's reputation as an immunologically 'cold' tumor. The studies, conducted in China, the United States, and Australia, underscore IBI363's potential to convert 'cold tumors' into 'hot tumors,' suggesting significant promise for broader clinical development and potential new treatment avenues in immunotherapy-resistant and cold tumor indications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.